Genitourinary Cancer

Top Story

Pembrolizumab improves OS in advanced urothelial carcinoma

Pembrolizumab improves OS in advanced urothelial carcinoma
February 17, 2017

Second-line pembrolizumab extended OS with a low rate of adverse events compared with chemotherapy in patients with platinum-refractory advanced urothelial carcinoma, according to a phase 3 study presented at the Genitourinary Cancers Symposium and published simultaneously in The New England Journal of Medicine.

“For the first time, after more than 30 years of clinical research, immunotherapy shows a survival advantage compared with chemotherapy in second-line metastatic urothelial cancer,” Joaquim Bellmunt, MD, PhD, associate professor of medicine at Harvard Medical School and director of the Bladder Cancer Center at Dana-Farber Cancer Institute, told HemOnc Today. “In Europe, vinflunine (Javlor, Pierre Fabre) was approved for second-line use, but with limited benefit.”

In the Journals Plus

Previous cancer affects future cancer incidence, mortality risk with pediatric GH therapy

February 17, 2017
In patients with previous cancers treated with recombinant human growth hormone therapy as children, researchers observed increased risks for both cancer incidence and…
Meeting News

Use of antibiotics could reduce efficacy of immunotherapy

February 14, 2017
Cancer worsened more quickly in patients who received antibiotics less than 1 month before starting immunotherapy, according to a retrospective analysis scheduled for…
Meeting News

Benefits of immunotherapy for advanced kidney cancer may persist after therapy cessation

February 13, 2017
Patients with advanced kidney cancer who stop
CME

The Patient with Castration-resistant Prostate Cancer

No commercial support for this activity.

Castration-resistant prostate cancer (CRPC) is a heterogeneous condition that encompasses a continuum of disease…
More »
Video
Meeting News Coverage

VIDEO: CABOSUN trial ‘changes the game’ of first-line renal cell carcinoma therapy

October 12, 2016
More »
Featured
CME

Breakthroughs in the Treatment of Bladder Cancer

This activity is supported by an educational grant from Bristol-Myers Squibb.

Assessment of immune checkpoint blockade inhibitors in the treatment of bladder cancer have demonstrated significant…
More »
In the Journals PlusPerspective

Pembrolizumab improves OS in advanced urothelial carcinoma

February 17, 2017
Second-line pembrolizumab extended OS with a low rate of adverse events compared with chemotherapy in patients with platinum-refractory advanced…

In the Journals Plus

Previous cancer affects future cancer incidence, mortality risk with pediatric GH therapy

February 17, 2017
In patients with previous cancers treated with recombinant human growth hormone therapy as children, researchers observed increased risks for both…

Meeting News

Use of antibiotics could reduce efficacy of immunotherapy

February 14, 2017
Cancer worsened more quickly in patients who received antibiotics less than 1 month before starting immunotherapy, according to a retrospective…

Meeting News

Benefits of immunotherapy for advanced kidney cancer may persist after therapy cessation

February 13, 2017
Patients with advanced kidney cancer who stop

FDA: More adolescents with cancer should be included in adult trials

February 13, 2017
Enrollment of adolescents in oncology trials remains significantly lower than that of children. Consequently, the FDA has urged the research…

In the Journals Plus

Use of metaphors may improve participation in clinical trials

February 11, 2017
The use of metaphors for explaining randomization could ease the difficulty in recruiting patients to participate in randomized clinical trials…

‘Explosive growth’ of interventional oncology prompts formation of new society

February 10, 2017
The board of directors for World Conference on Interventional Oncology, a nonprofit association that supports and promotes the field, has established…

Eight updates in cancer prevention

February 10, 2017
National Cancer Prevention Month, established by a U.S. Senate resolution and observed every February since 2004, is intended to draw attention to…

Evolution of surgery with hyperthermic intraperitoneal chemotherapy extends peritoneal cancer survival

February 10, 2017
Pseudomyxoma peritonei — which usually develops in the appendix — and peritoneal mesothelioma, which starts in the lining of the abdomen…

Payment reform, ‘runaway growth’ of 340B top new Community Oncology Alliance president’s priorities

February 9, 2017
Jeff Vacirca, MD, FACP, CEO and managing director of clinical research at New York Cancer Specialists in Long Island, N.Y., has been elected…

More Headlines »
Advertisement
Advertisement